6.01 USD
+0.23 (+3.98%)
At close: Feb 2, 2026
6 USD
-0.01 (-0.17%)
After Hours: 2/2/2026, 8:25:07 PM
We assign a fundamental rating of 5 out of 10 to MNKD. MNKD was compared to 524 industry peers in the Biotechnology industry. MNKD has only an average score on both its financial health and profitability. MNKD is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
- MNKD had positive earnings in the past year.
- In the past year MNKD had a positive cash flow from operations.
- MNKD had negative earnings in 4 of the past 5 years.
- The reported operating cash flow has been mixed in the past 5 years: MNKD reported negative operating cash flow in multiple years.
1.2 Ratios
- The Return On Assets of MNKD (5.81%) is better than 92.37% of its industry peers.
- MNKD has a Return On Invested Capital of 18.48%. This is amongst the best in the industry. MNKD outperforms 97.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.81% | ||
| ROE | N/A | ||
| ROIC | 18.48% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of MNKD (9.16%) is better than 90.84% of its industry peers.
- The Operating Margin of MNKD (27.48%) is better than 96.37% of its industry peers.
- MNKD has a Gross Margin of 78.49%. This is amongst the best in the industry. MNKD outperforms 84.73% of its industry peers.
- In the last couple of years the Gross Margin of MNKD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.48% | ||
| PM (TTM) | 9.16% | ||
| GM | 78.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MNKD is creating value.
- The number of shares outstanding for MNKD has been increased compared to 1 year ago.
- Compared to 5 years ago, MNKD has more shares outstanding
- Compared to 1 year ago, MNKD has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -5.13, we must say that MNKD is in the distress zone and has some risk of bankruptcy.
- MNKD's Altman-Z score of -5.13 is on the low side compared to the rest of the industry. MNKD is outperformed by 60.88% of its industry peers.
- MNKD has a debt to FCF ratio of 8.39. This is a slightly negative value and a sign of low solvency as MNKD would need 8.39 years to pay back of all of its debts.
- MNKD has a better Debt to FCF ratio (8.39) than 91.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 8.39 | ||
| Altman-Z | -5.13 |
ROIC/WACC2.16
WACC8.57%
2.3 Liquidity
- A Current Ratio of 3.29 indicates that MNKD has no problem at all paying its short term obligations.
- With a Current ratio value of 3.29, MNKD is not doing good in the industry: 60.69% of the companies in the same industry are doing better.
- A Quick Ratio of 3.04 indicates that MNKD has no problem at all paying its short term obligations.
- MNKD's Quick ratio of 3.04 is on the low side compared to the rest of the industry. MNKD is outperformed by 61.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.29 | ||
| Quick Ratio | 3.04 |
3. Growth
3.1 Past
- MNKD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 174.00%, which is quite impressive.
- Looking at the last year, MNKD shows a quite strong growth in Revenue. The Revenue has grown by 17.44% in the last year.
- Measured over the past years, MNKD shows a very strong growth in Revenue. The Revenue has been growing by 35.29% on average per year.
EPS 1Y (TTM)174%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%235%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%17.2%
3.2 Future
- Based on estimates for the next years, MNKD will show a very strong growth in Earnings Per Share. The EPS will grow by 52.41% on average per year.
- Based on estimates for the next years, MNKD will show a quite strong growth in Revenue. The Revenue will grow by 18.41% on average per year.
EPS Next Y-2.25%
EPS Next 2Y23.69%
EPS Next 3Y46.43%
EPS Next 5Y52.41%
Revenue Next Year20.77%
Revenue Next 2Y22.88%
Revenue Next 3Y19.82%
Revenue Next 5Y18.41%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 42.93, MNKD can be considered very expensive at the moment.
- Compared to the rest of the industry, the Price/Earnings ratio of MNKD indicates a rather cheap valuation: MNKD is cheaper than 91.22% of the companies listed in the same industry.
- The average S&P500 Price/Earnings ratio is at 28.41. MNKD is valued rather expensively when compared to this.
- Based on the Price/Forward Earnings ratio of 49.10, the valuation of MNKD can be described as expensive.
- 90.46% of the companies in the same industry are more expensive than MNKD, based on the Price/Forward Earnings ratio.
- MNKD is valuated expensively when we compare the Price/Forward Earnings ratio to 25.64, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.93 | ||
| Fwd PE | 49.1 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, MNKD is valued cheaper than 94.47% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, MNKD is valued cheaper than 92.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 42.53 | ||
| EV/EBITDA | 18.81 |
4.3 Compensation for Growth
- A more expensive valuation may be justified as MNKD's earnings are expected to grow with 46.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.69%
EPS Next 3Y46.43%
5. Dividend
5.1 Amount
- MNKD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
6.01
+0.23 (+3.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)02-24 2026-02-24/amc
Inst Owners57.07%
Inst Owner Change-0.88%
Ins Owners1.59%
Ins Owner Change1.09%
Market Cap1.85B
Revenue(TTM)313.79M
Net Income(TTM)28.75M
Analysts85.33
Price Target9.8 (63.06%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)53.26%
Min EPS beat(2)-100%
Max EPS beat(2)206.52%
EPS beat(4)1
Avg EPS beat(4)19.34%
Min EPS beat(4)-100%
Max EPS beat(4)206.52%
EPS beat(8)2
Avg EPS beat(8)-31.68%
EPS beat(12)5
Avg EPS beat(12)-2.87%
EPS beat(16)6
Avg EPS beat(16)-4.99%
Revenue beat(2)1
Avg Revenue beat(2)-2.11%
Min Revenue beat(2)-4.55%
Max Revenue beat(2)0.33%
Revenue beat(4)3
Avg Revenue beat(4)-0.74%
Min Revenue beat(4)-4.55%
Max Revenue beat(4)0.9%
Revenue beat(8)6
Avg Revenue beat(8)1.65%
Revenue beat(12)8
Avg Revenue beat(12)2.45%
Revenue beat(16)11
Avg Revenue beat(16)3.58%
PT rev (1m)6.13%
PT rev (3m)-9.08%
EPS NQ rev (1m)-22.99%
EPS NQ rev (3m)-43.84%
EPS NY rev (1m)-1.71%
EPS NY rev (3m)-17.43%
Revenue NQ rev (1m)0.88%
Revenue NQ rev (3m)13.28%
Revenue NY rev (1m)-0.12%
Revenue NY rev (3m)5.77%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 42.93 | ||
| Fwd PE | 49.1 | ||
| P/S | 5.88 | ||
| P/FCF | 42.53 | ||
| P/OCF | 37.77 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 18.81 |
EPS(TTM)0.14
EY2.33%
EPS(NY)0.12
Fwd EY2.04%
FCF(TTM)0.14
FCFY2.35%
OCF(TTM)0.16
OCFY2.65%
SpS1.02
BVpS-0.15
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.81% | ||
| ROE | N/A | ||
| ROCE | 22.37% | ||
| ROIC | 18.48% | ||
| ROICexc | 48.2% | ||
| ROICexgc | 50.4% | ||
| OM | 27.48% | ||
| PM (TTM) | 9.16% | ||
| GM | 78.49% | ||
| FCFM | 13.83% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 8.39 | ||
| Debt/EBITDA | 3.59 | ||
| Cap/Depr | 64.99% | ||
| Cap/Sales | 1.74% | ||
| Interest Coverage | 9.12 | ||
| Cash Conversion | 51.63% | ||
| Profit Quality | 150.89% | ||
| Current Ratio | 3.29 | ||
| Quick Ratio | 3.04 | ||
| Altman-Z | -5.13 |
F-Score8
WACC8.57%
ROIC/WACC2.16
Cap/Depr(3y)397.13%
Cap/Depr(5y)337.1%
Cap/Sales(3y)10.78%
Cap/Sales(5y)10.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)174%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%235%
EPS Next Y-2.25%
EPS Next 2Y23.69%
EPS Next 3Y46.43%
EPS Next 5Y52.41%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%17.2%
Revenue Next Year20.77%
Revenue Next 2Y22.88%
Revenue Next 3Y19.82%
Revenue Next 5Y18.41%
EBIT growth 1Y48.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y237.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y386.62%
OCF growth 3YN/A
OCF growth 5YN/A
MANNKIND CORP / MNKD FAQ
What is the fundamental rating for MNKD stock?
ChartMill assigns a fundamental rating of 5 / 10 to MNKD.
Can you provide the valuation status for MANNKIND CORP?
ChartMill assigns a valuation rating of 5 / 10 to MANNKIND CORP (MNKD). This can be considered as Fairly Valued.
Can you provide the profitability details for MANNKIND CORP?
MANNKIND CORP (MNKD) has a profitability rating of 5 / 10.
What are the PE and PB ratios of MANNKIND CORP (MNKD) stock?
The Price/Earnings (PE) ratio for MANNKIND CORP (MNKD) is 42.93 and the Price/Book (PB) ratio is -41.42.